about
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysisA nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patientsLong-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progressionReal-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis.Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients.Clinical and immunological aspects of HIV infection in drug addicts.Human immunodeficiency virus (HIV) seropositivity in intravenous (i.v.) drug abusers in three cities of Italy: possible natural history of HIV infection in i.v. drug addicts in Italy.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients.Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C.Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.Systemic Inflammatory Response Is a Prognostic Marker in HIV-Infected Patients with Hepatocellular Carcinoma.Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients.Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection.Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study).Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report.Characterization of GBV-C infection in HIV-1 infected patients.Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients.Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases.HIV-IgM serology.Surgical site infections after elective neurosurgery: a survey of 1747 patients.Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.
P50
Q34063630-1CA78752-A0E7-4121-870A-97B6FABAE675Q34637668-436145A1-E864-48E2-9FA4-0125DAF095A4Q35849745-62E537C5-9A27-4E88-9288-050E04587C7DQ37059020-4F20D6A3-4471-4524-83A1-DB9503E05C76Q37176312-52FE8B93-2D67-4372-A910-23A681DADCB0Q38453370-12B7D082-BDDD-4D58-BF9C-B0BABD1660D1Q38597807-8CFCE54F-C549-44AD-BB42-C7D92F6C98CDQ38879814-E510429A-702F-4F76-94CA-5C0ACA79C134Q38888859-B7E5182D-FCD3-47B3-BCB7-1FE9C3DF3F69Q39018310-EBE1BB9A-C9B0-4437-AC97-5F0671E8954EQ39275091-5D2A39CE-B9DA-4EAD-BCF5-9E1D6E26C423Q39299586-36261C6E-5363-48E8-9F7D-44452FEB1C45Q39301797-A39B35B7-DEA0-4E10-8EBC-B5E22077C13DQ40113130-942BE5BB-2692-47AF-99DE-DBF1F8B88507Q40237283-49EC8427-0E7F-4648-8E45-233EBFB4FA46Q40377822-A446A778-5C69-48F7-B3D5-94A10499CCDCQ40401740-2115B3A5-6283-4D5C-824E-4BA861557858Q40482870-6AAB24BF-2A9E-46AD-ACEF-AD66B727D3B5Q40667760-9985B9B7-4FB6-42B2-9FBA-84C45C0BB4E4Q40819897-52C32514-0D7D-402E-ADE2-1FA3CB513F61Q40856569-6A75141B-4D6C-4EC1-AAD8-A3DA0B9B4E9DQ41634185-8223E4D0-95E4-4390-948A-3EF1FBB3D659Q41936049-072E1A65-8B5A-4C7C-AD9C-6856C93D59F4Q42222997-C35A00E4-9316-4696-B538-FA664D2B3454Q42255783-405B5082-8BF6-4179-898D-1F0F48D7D5A2Q42269060-638F08F5-6474-46C4-B6B1-3BA8543C417FQ42288464-3196FCF0-CCAE-4855-B183-1E43A1214851Q42669638-80EE72DC-54E5-419F-9A8D-B9A4BF0B2D6FQ42980438-E6B1AC42-F597-46C6-A4F2-500F1B73BF70Q42985465-23327159-6243-45FF-A771-9CBD857D4C9CQ42987087-11066D50-47A5-462F-878B-7F6720CD98C3Q42988991-AFF4FD56-DC16-426A-8660-9DBC6A240538Q42989246-A7293E97-E2D2-435B-BBE3-954EEDD872EAQ42989330-E2B1B4C3-B11D-415E-8CAF-49B33A8CA70BQ43040429-628BD7E0-1C6C-41BF-B7E6-B288E2EABC38Q43040437-C7605FDA-C186-4526-A817-D77A7D4EF6C6Q43085980-9FD58600-7EBF-4667-A26B-BCBD5A21A744Q43765041-A978341C-370C-407D-8147-2C8FA9D7F4CEQ43835396-390BD324-A0A1-46A9-B8BD-D12153480DB0Q44470463-A6B43E1D-86D6-44A2-9C4F-4462C569E4C5
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Caterina Uberti-Foppa
@ast
Caterina Uberti-Foppa
@en
Caterina Uberti-Foppa
@es
Caterina Uberti-Foppa
@nl
Caterina Uberti-Foppa
@sl
type
label
Caterina Uberti-Foppa
@ast
Caterina Uberti-Foppa
@en
Caterina Uberti-Foppa
@es
Caterina Uberti-Foppa
@nl
Caterina Uberti-Foppa
@sl
prefLabel
Caterina Uberti-Foppa
@ast
Caterina Uberti-Foppa
@en
Caterina Uberti-Foppa
@es
Caterina Uberti-Foppa
@nl
Caterina Uberti-Foppa
@sl
P106
P21
P31
P496
0000-0001-5271-9138